Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
  • Investors
  • Careers

Combination Strategies to Defeat RAS-Addicted Cancers

September 22, 2021

Jan Smith

 

3rd Annual RAS-Targeted Drug Development Summit; September 21-23, 2021; held virtually

 

Download presentation
Return to Media Home

Latest Scientific Presentations

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Optimizing RAS Inhibition with Dual Blockade of Oncogenic and Wild-Type RAS
Combinations of Tri-complex KRAS(ON) Inhibitors with RAS Companion Inhibitors and Immunotherapies Improve Anti-tumor Activity and Abrogate Adaptive Resistance in Preclinical Tumor Models In Vivo
Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us